One of the most common questions in molecular oncology is how two experts can look at the same NGS report and reach different conclusions.
The answer is surprisingly simple: genomic testing generates data, but clinical interpretation generates decisions. The first is largely objective; the second involves judgment. Modern sequencing platforms are remarkably reliable at identifying genomic alterations. Determining what those alterations mean for a specific patient is far more complex, and that is where expert opinions diverge.
NGS reports do not make decisions
An NGS report can tell us a great deal about a tumor's genomic state. What it can tell us is concrete:
- which alterations are present
- the variant allele frequency (VAF)
- biomarker status
- potential treatment associations
What it cannot tell us is the one question that matters clinically:
“What should we do for this patient today?”
That question requires interpretation, and interpretation involves uncertainty.
Five reasons experts may disagree
When two reviewers reach different conclusions, the disagreement almost always traces back to one of five sources, and rarely to the data itself.
They may disagree about biology
Not every mutation drives a tumor. Some alterations are true drivers, others are passengers, and still others may represent emerging resistant clones. The same alteration can be read differently depending on how important the reviewer believes it is to the tumor's biology. The first disagreement is often not about treatment at all, it is about what is actually driving the cancer.
They may weigh evidence differently
Two experts may agree that a biomarker is potentially actionable and still disagree on what to do next, because not all evidence carries the same weight. One may prioritize prospective trials, regulatory approvals, and guideline-supported indications. Another may be more willing to consider small studies, retrospective data, biological rationale, and off-label opportunities. The disagreement here is about evidence quality rather than biology.
They may view risk differently
Every recommendation carries uncertainty. Some clinicians are comfortable pursuing a biologically rational but weakly supported option; others prefer to stay closer to established standards of care. Neither approach is automatically right or wrong, the difference reflects how much uncertainty each expert is willing to accept.
They may focus on different time horizons
One expert may ask what the best treatment is right now. Another may ask what preserves the most future options. These are not always the same thing, and treatment sequencing is one of the most common reasons experienced molecular oncologists disagree.
They may see different missing pieces
Sometimes disagreement arises not from the data itself, but from what is absent. One reviewer may consider the report sufficient; another may ask:
- whether RNA sequencing should be performed
- whether a repeat biopsy is needed
- whether a finding could represent clonal hematopoiesis (CHIP)
- whether germline testing is warranted
- whether tumor evolution has changed the biology since the original sample
Different assumptions about missing information lead to different conclusions.
Why disagreement is not necessarily a problem
Many people assume disagreement means one expert is right and the other is wrong. In reality, molecular oncology often operates in areas where certainty does not exist. The most important question is not whether all experts agree, it is whether the reasoning can be explained.
Good molecular interpretation is transparent.
It shows what assumptions were made, what evidence was used, where uncertainty exists, and why a recommendation was chosen. A recommendation should be understandable, not simply accepted.
The role of a structured second opinion
A second opinion is not valuable because it always changes the conclusion. It is valuable because it makes the reasoning visible.
- Sometimes it confirms the original interpretation.
- Sometimes it identifies an overlooked opportunity.
- Sometimes it reveals a hidden limitation.
In every case the goal is the same: to ensure that an important treatment decision rests on the strongest possible interpretation of the available data.
The reality of precision oncology
Genomic sequencing is increasingly standardized. Genomic interpretation is not. The same report can support more than one reasonable conclusion.
What matters is not whether experts disagree, but whether the reasoning behind a recommendation is biologically sound, evidence-based, and appropriate for the patient in front of us.
That is why precision oncology remains both a science and a clinical judgment.
This content is intended for educational purposes only. It does not constitute individual medical advice and should not replace evaluation by the treating physician.